Brufsky, A., Sparano, J. A., Tolaney, S. M., Gadi, V., Shafrin, J., Chai, X., Yang, F., Zhou, Z., Ganapathy, V., Auld, C., Sopher, G. M., Alexander, E., Bollu, V., Garrison, L. P. (2025). Economic evaluation of work productivity gains associated with ribociclib (RIB) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) early breast cancer (EBC) in the United States.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e23117